Sustainability
is deep rooted in all
our decision making
We always strive to do more in order to positively impact our patients consumers, employees, communities as well as our shareholders. We firmly believed that doing business with a conscience is integral in order to sustain our business success.
LATEST
News Updates
23 FEBRUARY 2026
Pharmaniaga Berhad (Pharmaniaga or the Group) recorded a Profit After Tax (PAT) of RM8.7 million for the fourth quarter ended 31 December 2025 (Q4FY2025), marking its eight consecutive profitable quarter and strengthening the Group’s financial recovery and momentum towards exiting PN17.
13 NOVEMBER 2025
Pharmaniaga Berhad (Pharmaniaga or the Group) continues to sustain its positive momentum towards exiting PN17 status, marking its seventh consecutive profitable quarter for the period ended 30 September 2025 (Q3 FY2025). This achievement underscores the Group’s resilient operational capabilities and steady business recovery trajectory.
26 AUGUST 2025
Pharmaniaga Berhad (Pharmaniaga or the Group) continues its positive momentum in the second quarter of its financial year ended 30 June 2025 (Q2 FY2025), marking key milestones across its financial, pharmaceutical, and logistics segments. Reinforcing its steady progress towards exiting Practice Note 17 (PN17) status, the Group recorded a Profit After Taxation (PAT) of RM4.2 million, a 9.5% increase from RM3.8 million posted in the corresponding quarter of the previous financial year (Q2 FY2024).
6 AUGUST 2025
Pharmaniaga Berhad (Pharmaniaga or the Group) has successfully completed its third and final critical milestone of its Regularisation Plan (RP), the Capital Reduction exercise, hence completed the RP and fully compliant with the Main Market Listing Requirements of Bursa Malaysia, a significant step that firmly sets the Group on course to exit Practice Note 17 (PN17) status latest by the first quarter of 2026.
31 JULY 2025
Pharmaniaga Berhad (Pharmaniaga or the Group) has today successfully completed two critical milestones of its Regularisation Plan (RP), the Rights Issue and Private Placement, thus positioning the Group firmly on track to exit its PN17 status.
INTEGRATED
REPORT
2024
_____________________